Last updated: October 2026 SKY-0515 is an oral Huntington’s disease treatment candidate being developed by Skyhawk Therapeutics. It uses a small-molecule approach intended to affect RNA processing and reduce production of the disease-causing huntingtin protein. Current status SKY-0515 is investigational and is not FDA approved. Its clinical development, trial results, regulatory path, eligibility, timing, and…